These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37031357)
1. ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy. Mo W; Liu S; Zhao X; Wei F; Li Y; Sheng X; Cao W; Ding M; Zhang W; Chen X; Meng L; Yao S; Diao W; Wei H; Guo H Adv Healthc Mater; 2023 Aug; 12(21):e2300191. PubMed ID: 37031357 [TBL] [Abstract][Full Text] [Related]
2. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression. Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384 [TBL] [Abstract][Full Text] [Related]
3. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307 [TBL] [Abstract][Full Text] [Related]
4. Nanozyme-Based Enhanced Cancer Immunotherapy. Phan NM; Nguyen TL; Kim J Tissue Eng Regen Med; 2022 Apr; 19(2):237-252. PubMed ID: 35099759 [TBL] [Abstract][Full Text] [Related]
5. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. Petty AJ; Li A; Wang X; Dai R; Heyman B; Hsu D; Huang X; Yang Y J Clin Invest; 2019 Dec; 129(12):5151-5162. PubMed ID: 31638600 [TBL] [Abstract][Full Text] [Related]
6. Blocking LTB Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900 [TBL] [Abstract][Full Text] [Related]
7. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569 [TBL] [Abstract][Full Text] [Related]
8. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772 [TBL] [Abstract][Full Text] [Related]
9. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. Zhao Y; Du J; Shen X Front Immunol; 2023; 14():1157537. PubMed ID: 37006306 [TBL] [Abstract][Full Text] [Related]
10. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy. Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878 [TBL] [Abstract][Full Text] [Related]
11. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy. Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739 [TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
13. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses. Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537 [TBL] [Abstract][Full Text] [Related]
14. Target tumor microenvironment by innate T cells. Li YR; Wilson M; Yang L Front Immunol; 2022; 13():999549. PubMed ID: 36275727 [TBL] [Abstract][Full Text] [Related]
15. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030 [TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy. Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974 [TBL] [Abstract][Full Text] [Related]